Another Question for Red
How significant can the cold chain storage requirements for mrna vaccines be in contributing to/exacerbating the efficacy variation and underperformance relative to clinical results? I think it would have to be taken as a given that worldwide distribution of these vaccines comes with any number of storage and transport excursions outside of cold storage specifications. I remember a post from you a while back where you indicated that this would not adulterate the product with any effect on safety...but would affect efficacy.
Novavax needs to hammer this point home in addition to the many other positives of its vaccine. I don't think it has received the driving emphasis that this positive aspect warrants.